BOYDSense has been selected by the European Innovation Council (EIC) Accelerator

Alpha MOS announces that its MedTech subsidiary BOYDSense has been selected by the European Innovation Council (EIC) Accelerator of the Horizon Europe funding program. This award recognizes the excellence of its work in medical innovation dedicated to the monitoring of chronic diseases. This €2.5M grant will accelerate the development of a miniaturized breath analyzer for blood glucose monitoring of pre-diabetics and type 2 diabetics.
The EIC Accelerator is the cornerstone of the Horizon Europe funding program (2021-2027) managed by the European Commission (EC) and the European Innovation Council (EIC).
It is a highly selective program for small and medium-sized enterprises (SMEs) that need
financial support to develop and industrialize an innovation.
Joining the EIC Accelerator of the Horizon Europe program is a decisive step for BOYDSense. Several thousand companies apply to this program each year and only a few dozen are selected. This program rewards the most innovative projects that strengthen European technological sovereignty.
Bruno Thuillier, founder and CTO of BOYDSense, comments on this decision: “It is a
significant achievement to have been selected among several thousand companies. This
signal demonstrates the EIC’s commitment to establish a European champion in non-
invasive chronic disease management, starting with diabetes.”
Pierre Sbabo, CEO of Alpha MOS, congratulates his teams: “I am pleased with this selection which demonstrates the quality of the innovation of the Alpha MOS group, as the competition was intense. This funding will allow us to accelerate the development of our non-invasive blood glucose measurement technology. This is a key step towards the future release of a commercial product for diabetics.”

About BOYDSense

BOYDSense, Inc. is a medical technology company developing affordable, non-invasive tools for measuring critical biomarkers via exhaled breath. Its mission is to build the platform for anywhere, anytime biosignature capture and display to help consumers better manage their conditions. Breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using them to diagnose and monitor chronic diseases, such as diabetes. The BOYDSense platform will also allow consumers and healthcare providers to use breath as a non-invasive medium to detect and monitor diseases like cancer, obesity, asthma, and others. BOYDSense’s first product under development, the g-Sense Breath Meter, is an affordable handheld device that allows people with diabetes to accurately measure blood glucose values through breath-based VOCs without the cost, pain, and social stigma associated with conventional fingerstick glucose testing. BOYDSense is an Alpha MOS company, the leader in volatile organic compound analysis.

For more information, please visit: